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Abstract
In July 2007 a subject died while enrolled in an arthritis gene
therapy trial. The study was placed on clinical hold while the
circumstances surrounding this tragedy were investigated. Early in
December 2007 the Food and Drug Administration removed the
clinical hold, allowing the study to resume with minor changes to
the protocol. In the present article we collate the information we
were able to obtain about this clinical trial and discuss it in the
wider context of arthritis gene therapy.
Introduction
On 24 July 2007 a 36-year-old woman with rheumatoid
arthritis (RA) died, 22 days after receiving a second dose of
an experimental, arthritis gene therapeutic [1]. The Food and
Drug Administration (FDA) placed the trial on hold while the
circumstances of the participant’s death were investigated;
the National Institutes of Health Recombinant DNA Advisory
Committee (RAC) launched a similar enquiry. At the
beginning of December 2007 the FDA allowed the trial to
proceed, suggesting that it did not attribute the subject’s
death to the gene treatment. A few days later, however, the
RAC concluded that a possible role of the gene transfer in
this clinical course cannot definitively be excluded due to the
lack of data (RAC Minutes of Meeting, December 3-5, 2007).
As the clinical trial restarts, we review the circumstances of
this tragedy in the larger gene therapy context and consider
the lessons to be learned.
Gene therapy in perspective
For much of its short history, gene therapy has suffered huge
mood swings. Enthusiasm ran high after the first properly
authorized gene transfer to a human in 1989 [2], but was
stilled instantly by the 1999 death of Jesse Gelsinger in a
gene therapy trial at the University of Pennsylvania [3]. A
more measured optimism returned when the first apparent
gene cures of X-linked severe combined immunodeficiency
were reported in the early 2000s [4], only to be dashed again
by the occurrence of leukemia in several of these subjects
[5]. Similar technology has been applied successfully to treat
X-linked chronic granulomatous disease [6], and the death of
a subject in a Swiss–German trial in 2006 was attributed to
the disease, not to the gene transfer [7].
Matters have been improving since then, with apparent cures
in several cases of X-linked severe combined immuno-
deficiency, adenosine deaminase severe combined immuno-
deficiency [8] and melanoma [9], and promising clinical
responses reported for Parkinson’s disease [10]. Thirty-two
phase III clinical trials are underway [11], and the first
commercially available gene therapy – Gendicin, for tumors of
the head and neck – has been launched in China [12]. Just
when circumstances were beginning to look promising again,
another gene therapy death was reported [1] – this time
involving gene therapy for arthritis (Table 1).
Arthritis gene therapy
Although not an obvious target for gene therapy, arthritis has
been on the agenda since the early 1990s when Bandara
and colleagues suggested delivering genes locally to the
synovial linings of diseased joints (Figure 1) [13]. This
strategy promises to provide therapies that are cheaper,
safer, more effective and longer lasting than existing ones.
The efficacy and safety of gene therapy approaches for treat-
ing arthritis have been demonstrated extensively in animal
models of disease involving mice, rats, rabbits, dogs and
horses [14].
Most of the envisaged clinical applications for treating
arthritis require sustained intraarticular transgene expression
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at fairly high levels. Nonviral gene transfer cannot fulfill these
requirements [15] and, with one exception, has not been
used in human clinical trials of arthritis (Table 2), despite its
popularity for certain other applications (Table 3). Several
recombinant, viral vectors have been used in human trials
(Table 3) – of which adenovirus, herpes simplex virus, vaccinia
and poxviruses give only transient transgene expression, so
attention has focused on retroviruses and adeno-associated
virus (AAV), which offer the prospect of long-term expression.
Most retrovirus vectors are derived from the Moloney murine
leukemia virus, and were the first to be developed for human
use [16]. The viruses integrate their genetic material into the
chromosomal DNA of the cells they infect, thereby providing
a basis for long-term expression of the transgene. Because
cell division is required for successful transduction by
Moloney-based vectors, they are usually used in an ex vivo
fashion. This method was used for the first two arthritis gene
transfer trials [17-19], in which IL-1 receptor antagonist
cDNA was transferred to the metacarpophalangeal joints of
subjects with RA (Table 2).
Although both of these studies confirmed that genes could
be successfully and safely transferred to human arthritic joints
in this fashion, with evidence of a favorable clinical response
[17-19], enthusiasm for the ex vivo, retrovirus-based
approach has waned because of cost and safety. Protocols
using retrovirus vectors are costly because of the need for
two invasive patient procedures and for ex vivo cell culture;
they raise safety concerns because of insertional
mutagenesis [20].
For nonlethal conditions such as arthritis, it is difficult to
justify the continued use of retrovirus vectors unless certain
additional safety procedures are used. In three of the four ex
vivo  protocols presented in Table 2, the retrovirally trans-
duced cells are surgically removed after injection. Additionally,
in the recent protocols for osteoarthritis (Table 2), the cells are
irradiated prior to intraarticular injection to prevent them from
Table 1
Deaths reported in human gene therapy trials
Death related to 
Year Disease target Vector Comment gene therapy? Ref.
1999 Ornithine transcarbamylase  Adenovirus Patient died within 4 days from cytokine  Yes [3]
deficiency storm elicited by infusion of vector
2002 X-linked severe combined  Retrovirus Leukemia developed, linked to insertion  Yes [5]
immunodeficiency of retrovirus adjacent to the LMO2 
oncogene promoter
2006 X-linked chronic  Retrovirus Loss of transgene expression led to  No [7]
granulomatous disease death from underlying disease
2007 Rheumatoid arthritis Adeno-associated Present article
virus
Figure 1
The basic concept – gene transfer to the synovium. Antiarthritic genes
are delivered intraarticularly to the individual joint, where their
expression leads to the accumulation of sustained, therapeutic levels
of the gene product. Reproduced with permission from Bandara and
colleagues [13].Page 3 of 9
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dividing, under which conditions they cannot form tumors.
These particular protocols also reduce the cost and
complexity of ex vivo gene transfer by using a transduced,
allogeneic cell line.
Most interest, however, has shifted to AAV as a safe,
injectable vector for the in vivo, local gene therapy of arthritis
[21].
Gene therapy with adeno-associated virus
vectors
AAV is a parvovirus with a 4.7 kb single-stranded DNA genome
[22]. The wild-type virus has only two genes, Rep and Cap,
and cannot replicate without the presence of a helper virus. In
nature the helper is often adenovirus, and AAV was first
isolated in association with adenovirus, hence its name. There
are multiple serotypes of AAV [23], but serotype 2 (AAV2)
has been used in nearly all human trials, including the arthritis
trial under discussion.
Although the production of large amounts of recombinant
AAV is difficult, recent improvements in technology have
lowered this barrier, leading to its greater use [24]. In the
past, the single-stranded genome of AAV presented another
limitation to its wider application. This limitation is that genes
within single-stranded AAV genomes cannot be expressed
unless the host cells successfully undertake second-strand
synthesis. Depending on the cell type, this synthesis can be
very inefficient. The recent development of self-complemen-
ting, double-stranded AAV genomes has eliminated this
problem for those cDNAs that are small enough to fit within
these now half-sized genomes [25]. Transgene expression
from self-complementing AAV is typically faster and far higher
than expression from the equivalent single-stranded virus.
Although up to 80% of human populations have circulating
antibodies against AAV2 as a result of silent infections, titers
Available online http://arthritis-research.com/content/10/3/110
Table 2
Human clinical trials of arthritis gene therapy
Vector, Principal  investigator,  OBA  Protocol 
Transgene ex vivo/in vivo Phase institution/sponsor Number Status n
IL-1 receptor  Retrovirus,  I Evans and Robbins, University of  9406-074 Closed 9
antagonist ex vivo Pittsburgh, USA
IL-1 receptor  Retrovirus,  I Wehling, University of Düsseldorf,  Not applicable Closed 2
antagonist ex vivo Germany
HSV-tka Plasmid, in vivo  I Roessler, University of Michigan, USA 9802-237 Closed 1
TNFR:Fc fusion  AAV, in vivo I Mease, Targeted Genetics Corp., USA 0307-588 Closed 15
protein 
(etanercept)
TGFβ1 Retrovirus, ex vivo I Ha, Kolon Life Sciences, Korea Not applicable Open 12
TGFβ1 Retrovirus, ex vivo I Mont, TissueGene Inc., USA 0307-594 Open 4
TNFR:Fc fusion  AAV, in vivo I/II Mease, Targeted Genetics Corp., USA 0504-705 Enrolled.  127
protein  Clinical hold 
(etanercept) lifted by FDA in 
December 2007
All of these trials target rheumatoid arthritis except for the TissueGene and Kolon trials, which target osteoarthritis. The Targeted Genetics Corp.
trial can also recruit subjects with psoriatic arthritis and ankylosing spondylitis. A phase I study injecting NF-κB decoy oligonucleotides is underway
at the University of Osaka in Japan (principal investigator: Tomita). This study is not included because it is not strictly gene therapy. Also omitted for
the same reason are two trials using TNF antisense RNA [14]. aWhen expressed in conjunction with ganciclivir administration, herpes simplex virus
thymidine kinase (HSV-tk) kills synovial cells and produces a synovectomy. AAV, adeno-associated virus; FDA, Food and Drug Administration; n,
number of subjects in study; OBA, Office of Biotechnology Activities; TGFβ1, transforming growth factor beta 1; TNFR:Fc, tumor necrosis factor
receptor:Fc domain of immunoglobulin fusion protein.
Table 3
Vectors used for human gene therapy trials
Number of  Percentage of 





Adeno-associated virus 47 3.5




Sourced from [11].of neutralizing antibodies are often low [26]. Until recently,
AAV was thought not to provoke cytotoxic T-lymphocyte
immune reactions, a huge advantage for both safety and
prolonged transgene expression. It was therefore a surprise
when vigorous cytotoxic T-lymphocyte reactions were
reported from a recent trial using AAV2 to deliver factor IX
cDNA to the livers of subjects with hemophilia. This led to
transient transaminitis and loss of factor IX expression [27].
As a result of this observation and related findings, the
immune response to AAV is undergoing a thorough re-
evaluation [28].
Wild-type AAV causes no known disease, and recombinant
AAV vectors have been used safely in gene therapy trials of a
number of single gene disorders, as well as of Parkinson’s
disease, Alzheimer’s disease and cancer. These trials have
involved approximately 600 subjects in 47 human trials, 36 of
them in the USA [11]. In addition, two large phase III trials for
prostate cancer using AAV are underway, and orphan drug
status has been granted recently by the European Union for
AAV-mediated gene therapy for familial lipoprotein lipase
deficiency. The whole field of gene therapy was therefore
shocked when a subject with RA died shortly after the
injection of recombinant AAV into her right knee joint [1].
The tgAAC94 protocols
The study in which the subject died is one of two clinical trials
sponsored by Targeted Genetics Corp. (Seattle, WA, USA),
a gene therapy company (Table 2). The Targeted Genetics
vector, tgAAC94, is a single-stranded recombinant AAV2
virus containing the complete coding sequence of a fusion
protein combining the extracellular domain of human tumor
necrosis factor receptor type II and the Fc domain of IgG1
(TNFR:Fc). The gene product is identical to etanercept
(Enbrel®; Amgen, Thousand Oaks, CA, USA), used to treat
patients with RA. Expression is under the transcriptional
control of a human cytomegalovirus immediate early promo-
ter. The tgAAC94 vector is injected locally into symptomatic
joints with the expectation that etanercept will be produced
intraarticularly and will confer a local therapeutic effect
(Figure 1).
Before a human clinical gene therapy trial can proceed in the
USA, it must be approved locally by the Institutional Review
Board and Biohazard Safety Committee, at the federal level
by the FDA and, if federally funded, by the RAC of the
National Institutes of Health. Many privately funded protocols
are also reviewed by the RAC. Unlike the FDA’s deliberations,
those of the RAC are in the public domain, and we have used
this as the primary source of much of the information about
the tgAAC94 protocols described in the present review,
which is otherwise unavailable to other researchers.
The phase I study was given public review by the RAC in
September 2003. The protocol presented to the RAC was a
randomized, double-blind, placebo-controlled, dose-escala-
tion study allowing the recruitment of up to 32 subjects with
RA, psoriatic arthritis or ankylosing spondylitis. The dose
escalation provided 1010, 1011 and 1012 DNase-resistant
particles (DRP) (equivalent to virus particles) per milliliter per
joint, with the volume of injected tgAAC94 depending on the
joint: knees, 5 ml; ankles, 2 ml; wrists, 1 ml; and metacarpo-
phalangeal joints, 0.5 ml. The primary outcome endpoint was
safety. Secondary endpoints included measures of efficacy,
transgene expression, antibody responses to vector and
evidence of vector spread to peripheral blood cells (Table 4).
Significantly, subjects in the trial were not allowed
concomitant anti-TNF therapy.
The study is now closed. It has not yet been published in the
refereed literature but, according to data presented at the
September 2007 meeting of the RAC, a total of 15 subjects
were enrolled, 14 with RA and one with ankylosing spon-
dylitis; 14 knee joints were treated, and one ankle joint. Four
joints received placebo injections, five joints received 1010
DRP/ml and six joints received 1011 DRP/ml, but the highest
proposed dose appears to have been omitted. No drug-
related serious adverse events were noted.
Unlike the phase I study, a subsequent phase I/II study was
exempt from public RAC review but was described publicly at
the September 2007 meeting of the RAC. Permission was
given to recruit 120 subjects with a more ambitious dose
escalation of 1011, 1012 and 1013 DRP/ml and in the same
target joints with the addition of elbows, which received
1.5 ml vector. The endpoints of the phase I/II study were
broadly similar to those of the phase I study, but included
evaluation of additional potential outcome measures. The
most important differences from the phase I study were the
possibility to include patients who were already taking
systemic TNF blockers and the administration of a second
injection of tgAAC94 (Table 4).
According to the protocol, 120 subjects in the phase I/II
study are divided into six cohorts of 20 individuals. The first
three cohorts receive 1011, 1012 or 1013 DRP tgAAC94/ml,
and cohorts 4 to 6 constitute a phase II expansion to increase
subject numbers. In each cohort of 20 subjects, 15 patients
receive tgAAC94 at the appropriate dose and five patients
receive placebo in a blinded fashion. In the subsequent,
nonblinded part of the protocol, subjects receive tgAAC94
12 to 30 weeks after the first injection.
When the trial was placed on clinical hold, 127 subjects had
been entered into the study – spread almost equally between
placebo and each of the three doses of tgAAC94. The
majority had RA. Approximately 50% to 60% of the subjects
were taking a TNF antagonist, most commonly etanercept,
either alone or in combination with one or more disease-
modifying antirheumatic drugs or prednisone; 52 subjects
had received a second dose of tgAAC94. Prior to the
subject’s death there had been eight serious adverse events,
Arthritis Research & Therapy    Vol 10 No 3 Evans et al.
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related to the protocol. Five subjects had notably elevated
liver function tests, but these resolved either spontaneously
or upon discontinuation of methotrexate or statin.
A dose-dependent increase in neutralizing antibody to the
AAV2 capsid was noted. Vector genomes were detected in
the peripheral blood cells of certain subjects, especially at the
highest dose, suggesting leakage of vector from the joint. It
was not possible to measure accurately the level of
etanercept expression in subjects on systemic TNF antago-
nists because of limitations in the assay method. No increase
in circulating levels of total TNF binding activity was reported,
however, in 16 subjects who were not taking systemic anti-
TNF therapy.
The first efficacy data were presented at the 2007 annual
meeting of the American College of Rheumatology [29]. A
higher percentage of subjects who received tgAAC94
reported improvements in joint symptoms, function, and pain
than those receiving placebo.
Case report
The subject was a 36-year-old Caucasian woman with a
15-year history of RA. She had been treated with disease-
modifying antirheumatic drugs since the early 1990s, and in
2002 enrolled in a clinical trial of etanercept. This was
discontinued in 2004 because of a flare, and she was
switched to the anti-TNF antibody, adalimumab (Humira®;
Abbott, Abbott Park, IL, USA). The subject’s right knee
remained persistently swollen and tender, and received 10
Available online http://arthritis-research.com/content/10/3/110
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Table 4




Cohort particles) Drug Placebo (drug only) Endpoints
Phase I (RAC 2003) Primary
11 0 10 6 2 Safety
21 0 11 62 Secondary
31 0 12 6 2 Changes in tenderness and swelling; injected and noninjected joints
4 TBD 6 2 American College of Rheumatology and Disease Activity Score scoring
Joint fluid cell counts
TNFR:Fc levels in joint fluid and serum
Serum neutralizing antibodies to adeno-associated virus serotype 2
Presence of tgAAC94 in peripheral blood mononuclear cells
Phase I/II (RAC 2007)
11 0 11 15 5 20 Primary
21 0 12 15 5 20 Safety
31 0 13 15 5 20 Secondary
Tenderness and swelling of injected joint
41 0 11 15 5 20 Time to second injection of study drug
51 0 12 15 5 20 Overall disease activity
61 0 13 15 5 20 TNFR:Fc protein levels in serum and synovial fluid
Serum anti-adeno-associated virus capsid neutralizing titers
Explore new outcome measures for single joints
Patient assessment
Functional assessment
Joint inflammation and damage on magnetic resonance imaging 
(select subjects)
RAC = Recombinant DNA Advisory Committee; TBD, to be determined – the highest safe dose, as determined from cohorts 1 to 3; TNFR:Fc =
tumor necrosis factor receptor:Fc domain of immunoglobulin fusion protein.intraarticular steroid injections between 2000 and 2006.
Methotrexate had been administered from 1994 to 1999,
discontinued due to anticipated pregnancy, and resumed in
2002. Prednisone had been administered since 1999. At the
time of enrolling in the gene therapy study, the patient was
taking adalimumab (40 mg subcutaneously every other week),
methotrexate (20 mg subcutaneously once per week) and
prednisone (2.5 mg once per day).
The patient enrolled into the study on 12 February 2007 and
was randomized to receive two injections of the highest dose
of tgAAC94; namely, 1013 DRP/ml (that is, 5 × 1013 total
DRP). The first dose was injected into her right knee on 26
February 2007. At the time of receiving the second injection
on 2 July, the subject reported fatigue and a low-grade fever
(99.6°F). The same evening she suffered nausea, vomiting,
high fevers and chills, followed by diarrhea and abdominal
pain. The symptoms persisted at fluctuating levels for several
days, and on 12 July 2007 she was admitted to a local
hospital with a temperature of 103°F and a blood pressure of
100/60 mmHg. Various antibiotics were administered, but by
17 July 2007 the patient’s hemoglobin levels began to drop;
coagulation and liver tests were abnormal, and there were
episodes of hypotension and respiratory distress requiring
intubation and inotropes. A blood transfusion was given and
acute renal failure developed.
On 18 July 2007 an ultrasound examination revealed an
organizing hematoma or hemorrhage in the left retroperitoneal
space. The patient also demonstrated worsening liver function,
and her physicians were concerned she may need a liver
transplant. The patient was subsequently transferred to the
University of Chicago. The results of a liver biopsy taken at
the University of Chicago were consistent with acute hepa-
titis without cirrhosis, so a transplant work-up was not
initiated. She was empirically covered with multiple anti-
biotics, and antifungals were initiated. Renal replacement
therapy was also initiated. Unfortunately, it proved impossible
to stop the retroperitoneal bleed despite massive transfusion
of blood products. It was not possible to identify the source
of the bleeding, which eventually led to an enormous
hematoma that compressed the abdominal organs and led to
impaired kidney and lung function. This created abdominal
compartment syndrome with subsequent worsening of the
subject’s hemodynamic status. Life support was withdrawn
on 24 July 2007 and the patient died 20 minutes later.
Autopsy confirmed the presence of a huge retroperitoneal
hematoma weighing at least 3.5 kg. This caused focal
infarction of the left kidney and pushed the diaphragm
upwards, compressing the lungs. Blood cultures drawn on
the day of the patient’s death turned positive for Histoplasma
capsulatum. Consistent with this, postmortem examination
found Histoplasma in the liver, lungs, bone marrow, spleen,
lymph nodes, thymus, kidney and brain. Granulomas, which
are essential for effective host defense against intracellular
pathogens, were not seen in spite of the abundant histo-
plasmosis. There was evidence of herpes simplex virus in
certain tissues, but not adenovirus or cytomegalovirus. Oddly,
the pathological examination found no evidence of active RA
in either knee.
Quantitative PCR identified trace amounts of vector genomes
in the blood, spleen, liver and brain of the subject, larger
amounts in the tonsils and high copy numbers in the right
knee. The left knee, lymph nodes, heart, bladder, small bowel,
trachea and adrenals were negative. Rep gene sequences
that are absent from tgAAC94 and whose presence might
indicate replication-competent AAV were detected in the
heart, trachea and right knee, but not in the blood, spleen,
liver, brain or tonsils.
The most probable cause of death was disseminated histo-
plasmosis in conjunction with the retroperitoneal hematoma.
Histoplasmosis is a recognized risk factor when taking TNF
antagonists such as adalimumab and etanercept; moreover,
the subject lived in an area where H. capsulatum is endemic.
Histoplasmosis normally occurs 1 to 6 months after initiating
anti-TNF therapy, however, and the subject had been on
these drugs since 2002. Nevertheless, the most probable
explanation is that the subject was already infected with the
fungus when she received her second injection of tgAAC94,
a conclusion that agrees with her slightly elevated tempera-
ture and fatigue. It is less easy to explain all aspects of the
retroperitoneal bleed and this remains an enigma, although
mycotic aneurysm is a leading but unproven hypothesis.
Potential involvement of tgAAC94
Broadly speaking, serious adverse events could arise from
either the AAV virions themselves or from the etanercept
encoded by the transgene. As noted, twild-type AAV is not
known to cause disease. Recombinant AAV does not inte-
grate into the host genome, encodes no viral genes, is not
highly inflammatory, and has been used safely in 47 previous
human clinical gene therapy trials. Unlike previous trials using
AAV, however, the virus was readministered. This readminis-
tration could have led to a severe immunologic reaction in the
now sensitized patient, and indeed neutralizing antibodies to
AAV2 were generated in response to administration of the
tgAAC94 despite the immunosuppressive drugs she was
taking. There is no information on the role of TNF in host
defense to AAV.
If immune complex formation led to pathology, we would have
expected to see this most vigorously within the injected joint,
producing a human version of antigen-induced arthritis.
Ironically, of all the organs examined during the autopsy, the
knees seemed one of the least affected by recent disease.
None of the other organs examined showed signs of immune
complex disease either, but interpretation is complicated by
the immunosuppressive drugs being taken by the patient. It is
difficult, however, to implicate a humoral immune reaction to
Arthritis Research & Therapy    Vol 10 No 3 Evans et al.
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ber 2007 meeting the RAC considered the possible involve-
ment of cell-mediated immunity. Because the appropriate
samples were not kept, it will not be possible to exclude this
possibility.
It is difficult to see how the production of large amounts of
etanercept within the knee joint as a result of local gene
transfer could be lethal, especially as it is well established
from animal models that very little, if any, transgene product
can be measured in the peripheral blood unless intraarticular
transgene expression is extremely high [30,31]. The spread
and replication of tgAAC94, however, could lead to large
amounts of etanercept being produced throughout the body,
combining with adalimumab to elevate the total TNF-binding
capacity to levels that permitted a confined, subclinical
infection with Histoplasma to explode into a lethal, dissemi-
nated infection.
Several lines of evidence argue against this possibility. It
would have required the coinfection of a cell with tgAAC94,
wild-type AAV and a helper virus. The most effective helper
virus is adenovirus, and this was not detected in the patient.
Herpes simplex virus was present, but provides much weaker
help. Moreover, using sensitive PCR techniques, it was not
possible to detect large numbers of AAV genomes
throughout the body, although more than 3 weeks passed
before this was analyzed.
Because the subject died shortly after receiving a second
injection of tgAAC94, scant attention has been paid to a
possible role of the first injection delivered approximately
4 months earlier. The total TNF-binding capacity of the serum
increased progressively from 5.4 μg/ml before the first
injection of tgAAC94 to 8.6 μg/ml at the time of the second
injection. The latter value is within the normal range for
patients taking adalimumab, but is above the level present in
the subject’s serum before starting gene therapy. The steady
rise in serum anti-TNF after the first injection is intriguing
because transgene expression from single-stranded AAV
vectors such as tgAAC94 is also progressive. Based upon
her erythrocyte sedimentation rate and C-reactive protein
levels, the subject had no evidence of systemic inflammation
prior to the first injection, yet developed fluctuating but
impressive increases in erythrocyte sedimentation rate over
the subsequent several months. At the same time, there was
no indication of increased RA activity. This raises the possi-
bility that an infection, such as histoplasmosis, emerged
shortly after the first administration of tgAAC94 (M. Crow,
personal communication).
Further consideration of this possibility begs the question of
how an intraarticular injection of tgAAC94 could influence
serum levels of anti-TNF given our earlier statement that gene
products expressed intraarticularly do not escape from the
joint. In response, we can point to studies (for example [32])
noting that even experienced orthopedic surgeons can miss
the intraarticular space when attempting to inject knee joints.
Although circumstantial evidence appears to link gene
transfer to the subject’s death, it remains difficult to identify a
totally convincing, detailed scenario through which tgAAC94
could have been the critical factor in her demise. This seems
to be the conclusion of the FDA, which has allowed the study
to proceed.
Lessons learned
Although gene transfer may not have played a role in the death
of this patient, the episode identifies certain issues with the
design and execution of the clinical trial that are worth airing.
The most controversial aspect of the study is the injection of
etanercept cDNA into the joints of subjects who are already
taking TNF antagonists. Such dosing is based on the notion
that symptomatic joints in a patient who is otherwise
responding to TNF antagonists will benefit from additional,
locally produced etanercept. The assumption is that these
joints, unlike the responsive joints, receive insufficient TNF
antagonist from the circulation. This is an interesting and
plausible hypothesis, but it is difficult to find supporting
evidence in the refereed literature. The study in question
could help provide such evidence, were there a validated
outcome measure for assessing disease severity in individual
rheumatoid joints. The commonly used American College of
Rheumatology and Disease Activity Score systems are of little
use here, however, because they measure global changes in
large numbers of joints.
Evaluating efficacy was further complicated by the lack of
control over background drugs. Thus it would be impossible
to know whether any changes in a joint were due to gene
transfer or due to some other drug the individual was taking,
especially in rheumatic diseases with their flares and
remissions. The ability to recruit from three different diseases
(RA, psoriatic arthritis, ankylosing spondylitis) and inject one
of five different joints only complicates matters further.
The subject had previously taken etanercept for 2 years and
switched to adalimumab when symptoms flared. This raises
the possibility that she was one of those patients who stop
responding to etanercept, in which case administering
etanercept cDNA might have been pointless. Some commen-
tators have questioned further the clinical judgment of
injecting the trial subject with vector when she was already ill.
Indeed, the possibility that the symptoms affecting the right
knee joint were not caused by RA but some other condition,
such as secondary osteoarthritis, has also been suggested.
Moreover, her transfer to a local hospital raises issues of the
investigative environment.
Assessing the possible benefit of the etanercept gene is
further hindered by the study’s inability to measure etanercept
Available online http://arthritis-research.com/content/10/3/110
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questions pertinent to any gene therapy protocol is the level
and duration of transgene expression. To initiate a clinical trial
without the tools to measure this is peculiar. According to
Targeted Genetics’ 2003 RAC submission, the company was
developing an ELISA for this purpose. At the September 2007
RAC meeting, however, it became evident that a radio-
immunoassay was being used, and this could not distinguish
between etanercept and other TNF-binding agents. During the
same RAC meeting it was stated that an etanercept-specific
ELISA was being requested from Amgen (Thousand Oaks, CA,
USA), but data from this source seem unavailable at present.
Measuring the total TNF-binding activity of the serum tells us
nothing about the key therapeutic question of how much
etanercept was expressed in the joints. Expression levels may
be modest because tgAAC94 is a single-stranded AAV
vector. Moreover, when carrying a green fluorescent protein
transgene instead of etanercept, the vector only transduced a
few percent of human synovial fibroblasts in vitro, according
to the 2003 RAC documents. Synovial fluids are presumably
available from subjects who were not on anti-TNF to allow
measurements to be made without interference. One such
fluid from a subject who received 1012 DRP/ml has so far
been analyzed, and the TNF-binding activity was below the
level of detection.
The phase I/II study was allowed to go ahead when less than
one-half of the subjects from the phase I trial had been
treated, when the high dose of vector had not been adminis-
tered and when several secondary objectives had not been
accomplished. The reasons for curtailing the phase I study
while permitting the phase I/II study are not publicly known,
but it raises issues of oversight and data reporting that may
be worthy of further discussion in the appropriate forum.
Restarting the trial
Now that the FDA has lifted the clinical hold on the trial, the
study can proceed in a slightly modified fashion. Vector cannot
be given to subjects with a temperature greater than 98.6°F,
with localizing signs and symptoms, or with unexplained fatigue
or malaise on the day of administration. Patients with a history
of opportunistic infection are excluded and patients are
required to have failed at least one disease-modifying
antirheumatic drug. Subjects who will receive a second dose of
tgAAC94 will first sign a revised informed consent.
The FDA is also requiring additional monitoring, including
blood draws at additional timepoints after administration of
study agent for complete blood counts, serum chemistry,
vector DNA, TNFR:Fc protein and potential T-cell responses
to AAV2 capsid.
Conclusion
In a recent review on arthritis gene therapy we argued for
more clinical trials but cautioned that the ‘acceptance of a
gene therapy approach for nongenetic, nonlethal diseases
such as arthritis is marginal …, and a serious adverse event
could destroy the entire enterprise’ [14]. The case currently
under discussion has given the field a scare, but it seems that
the authorities are not holding gene transfer responsible for
the subject’s tragic death. The logic behind a local, intra-
articular gene therapy approach to treating arthritis remains
as compelling as it did when first published over 15 years ago
[13], and we continue to believe it will eventually form part of
the clinical armamentarium [33]. Examination of the clinical
trial fatality has raised certain matters for further discussion,
and collegial, dispassionate and reasoned consideration
should help us all to develop the safe and informative clinical
trials needed to move this area forward.
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